IOVANCE BIOTHERAPEUTICS, INC.
IOVA · XNASCIK 1425205fmd_0S20TTYV8HQYNWRVG9JVEZVHZBManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2008 to Sep 30, 2026, 68 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | – | – | – | – | 1 | 164 | 264 |
| Net interest income | – | – | – | – | – | – | – | – | – | – |
| Cost of revenue | – | – | – | – | – | – | – | 1 | 93 | 173 |
| Gross profit | – | – | – | – | – | – | – | 0 | 71 | 90 |
| Research and development | 27 | 72 | 100 | 166 | 202 | 259 | 295 | 333 | 276 | 300 |
| Total operating expenses | 54 | 93 | 128 | 207 | 262 | 343 | 399 | – | – | – |
| Operating income | (54) | (93) | (128) | (207) | (262) | (343) | (399) | (461) | (395) | (403) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Interest and investment income | 1 | 1 | 5 | 9 | 2 | 0 | 3 | 13 | 20 | 10 |
| Other non-operating income (expense) | – | – | – | – | – | – | – | – | – | – |
| Income before taxes | – | – | – | – | – | (342) | (396) | (448) | (375) | (393) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (3) | (3) | (2) |
| Net income from continuing operations | – | – | – | – | – | (342) | (396) | (444) | (372) | (391) |
| Net income | (53) | (92) | (124) | (198) | (260) | (342) | (396) | (444) | (372) | (391) |
| Net income to common shareholders | (102) | (92) | (124) | – | – | – | – | – | – | – |